Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Medical Device

China Isotope & Radiation Corporation Showcases C-14 Barium Carbonate at International Symposium

Fineline Cube Jul 2, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) announced that it showcased its C-14 barium...

Company Deals

Merck KGaA Completes $3.4 Billion Acquisition of SpringWorks Therapeutics Boosting Rare Oncology Portfolio

Fineline Cube Jul 2, 2025

German pharmaceutical giant Merck KGaA (ETR: MRK) has completed its USD 3.4 billion (EUR 3...

Company Drug

Allergan Aesthetics’ SKINVIVE by JUVÉDERM Accepted for FDA Review to Reduce Neck Lines

Fineline Cube Jul 2, 2025

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that the supplemental premarket approval (sPMA) application...

Company Deals

Hybio and iCarbonX Enter CRDMO Service Pact and Strategic Investment to Advance Peptide Drug Pipeline

Fineline Cube Jul 2, 2025

This week, China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) and iCarbonX entered into an innovative...

Company Deals

EnChannel Medical Acquires AcQMap Platform Assets from Acutus Medical to Strengthen Non-Contact Mapping Tech

Fineline Cube Jul 2, 2025

Guangzhou-based electrophysiology platform company EnChannel Medical Ltd. is set to acquire the AcQMap High Resolution...

Company Deals

Jiangsu Hengrui Pharmaceuticals Partners with NSFC to Establish Private Enterprise Innovation Fund

Fineline Cube Jul 2, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced an agreement with the National...

Company Deals

Sanofi Invests $25 Million in China’s Adagene to Advance SAFEbody Program

Fineline Cube Jul 2, 2025

French pharmaceutical major Sanofi (NASDAQ: SNY) is set to make a USD 25 million investment...

Policy / Regulatory

NHSA Unveils Plans for 2025 National Drug List Adjustments and Commercial Insurance Drug List

Fineline Cube Jul 2, 2025

This week, China’s National Healthcare Security Administration (NHSA) released two draft documents detailing a plan...

Company Deals

Esteve to Acquire Sanofi’s Caprelsa Rights in Over 50 Countries for Medullary Thyroid Cancer Treatment

Fineline Cube Jul 2, 2025

Spanish multinational pharmaceutical company Esteve, which also operates an industrial site in China, is set...

Company Deals

AbbVie to Acquire Capstan Therapeutics for Its First-in-Class CAR-T Candidate

Fineline Cube Jul 1, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) is poised to acquire fellow American firm Capstan Therapeutics,...

Others

Chia Tai Tianqing’s Anlotinib Granted NMPA Approval for Soft Tissue Sarcoma

Fineline Cube Jul 1, 2025

China-based Chia Tai Tianqing Pharmaceutical announced that its anlotinib (trade name: FOCUS V) has received...

Company Drug

Huadong Medicine’s First-in-Class ADC HDM2012 Gains FDA Phase I Trial Clearance

Fineline Cube Jul 1, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clearance from the...

Policy / Regulatory

China Unveils Measures to Boost Innovative Drug Development With Insurance Data Support

Fineline Cube Jul 1, 2025

China’s National Healthcare Security Administration (NHSA) and National Health Commission (NHC) jointly released the “Several...

Company Deals Drug

HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC

Fineline Cube Jul 1, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from...

Company Deals

Recbio Partners with Biological E for HPV VaccineREC603’s India and Global Expansion

Fineline Cube Jul 1, 2025

China-based Jiangsu Recbio Technology Co., Ltd. (HKG: 2179) announced a licensing agreement with India-headquartered Biological...

Company Drug

Astellas Pharma’s Vyloy Gains First Prescriptions Across China for Gastric Cancer

Fineline Cube Jul 1, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) announced that the first prescriptions for Vyloy (zolbetuximab) in...

Others

Guangdong Announces First Batch of Approved Innovative Drugs and Medical Devices

Fineline Cube Jul 1, 2025

Departments including the Department of Industry and Information Technology, Health Commission, Healthcare Security Administration, and...

Company Drug

Santen’s Tapcom Administered to First Patient in GBA via Drug Access Policy

Fineline Cube Jul 1, 2025

Japan-based Santen Pharmaceutical Co., Ltd. announced that its novel glaucoma treatment, Tapcom (tafluprost/timolol maleate), has...

Company Deals

Zhaoke Ophthalmology Partners with Jamjoom Pharma for Cyclosporine Eye Gel Distribution in Middle East

Fineline Cube Jul 1, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced a partnership with Jamjoom Pharma, a leading Saudi...

Company Drug

Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio

Fineline Cube Jul 1, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of...

Posts pagination

1 … 126 127 128 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.